GRAIL, Inc.
@grailbio.bsky.social
GRAIL's mission is to detect cancer early, when it can be cured.
https://grail.com/
Community Guidelines: https://bit.ly/3xigb24
https://grail.com/
Community Guidelines: https://bit.ly/3xigb24
Early stage pancreatic cancer often goes undetected, resulting in many people being diagnosed after the cancer has advanced.This Pancreatic Cancer Awareness Day, help us spread the word that #EarlyCancerDetection saves lives.
#PancreaticCancerAwareness
#PancreaticCancerAwareness
November 20, 2025 at 4:09 PM
Early stage pancreatic cancer often goes undetected, resulting in many people being diagnosed after the cancer has advanced.This Pancreatic Cancer Awareness Day, help us spread the word that #EarlyCancerDetection saves lives.
#PancreaticCancerAwareness
#PancreaticCancerAwareness
November 12, 2025 at 9:18 PM
Join us next Thursday for GRAIL’s Analyst Day 2025. Register and watch the live webcast here: https://bit.ly/47K19Ue
November 7, 2025 at 4:23 PM
Join us next Thursday for GRAIL’s Analyst Day 2025. Register and watch the live webcast here: https://bit.ly/47K19Ue
On the latest episode of The Cancer SIGNAL podcast, host Susanna Quinn is joined by Nima Nabavizadeh, MD, from Oregon Health & Science University, to discuss the groundbreaking PATHFINDER 2 study findings. Listen here: https://bit.ly/48DGcwp
#EarlyCancerDetection #MCED
#EarlyCancerDetection #MCED
October 23, 2025 at 4:05 PM
On the latest episode of The Cancer SIGNAL podcast, host Susanna Quinn is joined by Nima Nabavizadeh, MD, from Oregon Health & Science University, to discuss the groundbreaking PATHFINDER 2 study findings. Listen here: https://bit.ly/48DGcwp
#EarlyCancerDetection #MCED
#EarlyCancerDetection #MCED
Today we announced that we have entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses. Learn more: grail.com/press-releas...
October 20, 2025 at 4:43 PM
Today we announced that we have entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses. Learn more: grail.com/press-releas...
70% of cancer deaths are from cancers that do not have recommended screening tests. In the PATHFINDER 2 study, presented at #ESMO25, approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. Learn more: https://bit.ly/4n91cP6
October 19, 2025 at 1:15 PM
70% of cancer deaths are from cancers that do not have recommended screening tests. In the PATHFINDER 2 study, presented at #ESMO25, approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. Learn more: https://bit.ly/4n91cP6
Coming up tomorrow at #ESMO25 in Berlin - results from the PATHFINDER 2 study. See our press release for more details: https://bit.ly/4n91cP6
October 17, 2025 at 10:53 PM
Coming up tomorrow at #ESMO25 in Berlin - results from the PATHFINDER 2 study. See our press release for more details: https://bit.ly/4n91cP6
It’s #MensBreastCancerAwareness Week, an ideal time to remind everyone that, while rare, #MenGetBreastCancerToo—and they should see their doctor immediately if they notice any unusual symptoms.
#EarlyDetection can help improve their chances for successful treatment.
#EarlyDetection can help improve their chances for successful treatment.
October 14, 2025 at 7:15 PM
It’s #MensBreastCancerAwareness Week, an ideal time to remind everyone that, while rare, #MenGetBreastCancerToo—and they should see their doctor immediately if they notice any unusual symptoms.
#EarlyDetection can help improve their chances for successful treatment.
#EarlyDetection can help improve their chances for successful treatment.
#LiverCancer is the fourth most common cause of cancer death worldwide, and hepatocellular carcinoma (HCC), which accounts for nearly 75% of all cases, is often diagnosed in advanced stages. We’re observing #LiverCancerAwarenessMonth by promoting #EarlyDetection.
#OctoberIs4Livers
#OctoberIs4Livers
October 10, 2025 at 7:55 PM
#LiverCancer is the fourth most common cause of cancer death worldwide, and hepatocellular carcinoma (HCC), which accounts for nearly 75% of all cases, is often diagnosed in advanced stages. We’re observing #LiverCancerAwarenessMonth by promoting #EarlyDetection.
#OctoberIs4Livers
#OctoberIs4Livers
After 20 years of serving her local police department, Darla took a multi-cancer early detection (MCED) test through her insurance company. Despite having no symptoms, her test detected a cancer signal, giving her the chance to take swift action and become cancer free today. https://bit.ly/47aCE3o
October 7, 2025 at 6:47 PM
After 20 years of serving her local police department, Darla took a multi-cancer early detection (MCED) test through her insurance company. Despite having no symptoms, her test detected a cancer signal, giving her the chance to take swift action and become cancer free today. https://bit.ly/47aCE3o
How do we bring multi-cancer early detection (MCED) into everyday clinical practice? With more than 35,000 participants, PATHFINDER 2 is the largest U.S. interventional MCED study to date. Ahead of #ESMO25, our president, Dr. Josh Ofman, shares what these data mean: https://bit.ly/46EECck
October 6, 2025 at 7:37 PM
How do we bring multi-cancer early detection (MCED) into everyday clinical practice? With more than 35,000 participants, PATHFINDER 2 is the largest U.S. interventional MCED study to date. Ahead of #ESMO25, our president, Dr. Josh Ofman, shares what these data mean: https://bit.ly/46EECck
For #BreastCancerAwarenessMonth, we’re calling out the importance of #EarlyDetection—especially if you’re at risk for the BRCA gene mutation. Learn more by listening to The Cancer SIGNAL: https://bit.ly/4pTkTxc
October 1, 2025 at 4:03 PM
For #BreastCancerAwarenessMonth, we’re calling out the importance of #EarlyDetection—especially if you’re at risk for the BRCA gene mutation. Learn more by listening to The Cancer SIGNAL: https://bit.ly/4pTkTxc
Celebrate #InternationalPodcastDay by giving The Cancer SIGNAL a listen. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)—from patients to doctors, advocates to researchers, and more. Tune in today: https://bit.ly/47oQpMD
#PodcastCommunity #EarlyCancerDetection
#PodcastCommunity #EarlyCancerDetection
September 30, 2025 at 6:53 PM
Celebrate #InternationalPodcastDay by giving The Cancer SIGNAL a listen. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)—from patients to doctors, advocates to researchers, and more. Tune in today: https://bit.ly/47oQpMD
#PodcastCommunity #EarlyCancerDetection
#PodcastCommunity #EarlyCancerDetection
#GynecologicCancerAwarenessMonth serves as a reminder of the importance of routine screenings for detecting cervical cancer early and improving prognosis and treatment success.
#GCAM #PreventCervicalCancer
#GCAM #PreventCervicalCancer
September 26, 2025 at 7:08 PM
#GynecologicCancerAwarenessMonth serves as a reminder of the importance of routine screenings for detecting cervical cancer early and improving prognosis and treatment success.
#GCAM #PreventCervicalCancer
#GCAM #PreventCervicalCancer
Tad Carper, a @dallas--cowboys.bsky.social exec, took a multi-cancer early detection (MCED) test—which led to an unexpected journey. Hear how early detection shaped his story on the latest episode of The Cancer SIGNAL podcast:
Apple Podcasts: https://apple.co/4mI2WPm
Apple Podcasts: https://apple.co/4mI2WPm
September 24, 2025 at 4:29 PM
Tad Carper, a @dallas--cowboys.bsky.social exec, took a multi-cancer early detection (MCED) test—which led to an unexpected journey. Hear how early detection shaped his story on the latest episode of The Cancer SIGNAL podcast:
Apple Podcasts: https://apple.co/4mI2WPm
Apple Podcasts: https://apple.co/4mI2WPm
We’re presenting new data from our PATHFINDER 2 study at the European Society for Medical Oncology 2025 Congress. We are also pleased to be sharing results from our SYMPLIFY and REFLECTION studies at the 2025 Early Detection of Cancer Conference. Read more: https://bit.ly/4nc39Lu #ESMO25
September 23, 2025 at 10:55 PM
We’re presenting new data from our PATHFINDER 2 study at the European Society for Medical Oncology 2025 Congress. We are also pleased to be sharing results from our SYMPLIFY and REFLECTION studies at the 2025 Early Detection of Cancer Conference. Read more: https://bit.ly/4nc39Lu #ESMO25
You can observe #WorldLymphomaAwarenessDay by putting your health first and paying attention to unusual symptoms—especially if you’re at high risk for lymphoma—as well as getting regular checkups. Remember that early detection can help ensure more treatment options.
#WLAD
#WLAD
September 15, 2025 at 7:13 PM
You can observe #WorldLymphomaAwarenessDay by putting your health first and paying attention to unusual symptoms—especially if you’re at high risk for lymphoma—as well as getting regular checkups. Remember that early detection can help ensure more treatment options.
#WLAD
#WLAD
A few compelling numbers in time for Ovarian Cancer Awareness Month: Stage I can be cured in up to 90% of cases, and stage II has a 5-year survival rate of 70%. Yet only 20% are diagnosed at stage I or II, underscoring the need to raise awareness of early detection.
#OvarianCancer #OCAM
#OvarianCancer #OCAM
September 9, 2025 at 6:49 PM
A few compelling numbers in time for Ovarian Cancer Awareness Month: Stage I can be cured in up to 90% of cases, and stage II has a 5-year survival rate of 70%. Yet only 20% are diagnosed at stage I or II, underscoring the need to raise awareness of early detection.
#OvarianCancer #OCAM
#OvarianCancer #OCAM
Were you aware that while the overall cancer death rate decreased by 34% from 1991 to 2022, the leukemia rate has increased? In observance of Blood Cancer Awareness Month, we’re highlighting the importance of early detection.
#BloodCancerAwareness #Leukemia
#BloodCancerAwareness #Leukemia
September 4, 2025 at 7:07 PM
Were you aware that while the overall cancer death rate decreased by 34% from 1991 to 2022, the leukemia rate has increased? In observance of Blood Cancer Awareness Month, we’re highlighting the importance of early detection.
#BloodCancerAwareness #Leukemia
#BloodCancerAwareness #Leukemia
August 12, 2025 at 8:42 PM
July is Sarcoma Awareness Month—a time to raise awareness about rare cancers and the importance of early detection. Cancer screenings and a knowledge of symptoms can lead to earlier diagnoses and better treatment outcomes. #SarcomaAwareness #EarlyCancerDetection
July 8, 2025 at 3:35 PM
July is Sarcoma Awareness Month—a time to raise awareness about rare cancers and the importance of early detection. Cancer screenings and a knowledge of symptoms can lead to earlier diagnoses and better treatment outcomes. #SarcomaAwareness #EarlyCancerDetection
Today we announced positive top-line performance and safety results from our registrational PATHFINDER 2 study.
Learn more: grail.com/press-releas...
Learn more: grail.com/press-releas...
June 18, 2025 at 1:12 PM
Today we announced positive top-line performance and safety results from our registrational PATHFINDER 2 study.
Learn more: grail.com/press-releas...
Learn more: grail.com/press-releas...
Today GRAIL reported first quarter 2025 financial results. Learn more: grail.com/press-releas...
May 13, 2025 at 8:32 PM
Today GRAIL reported first quarter 2025 financial results. Learn more: grail.com/press-releas...
Today we announced a new partnership with athenahealth, which will offer healthcare providers streamlined ordering of the Galleri multi-cancer early detection (MCED) test.
Learn more: grail.com/press-releas...
Learn more: grail.com/press-releas...
May 12, 2025 at 8:09 PM
Today we announced a new partnership with athenahealth, which will offer healthcare providers streamlined ordering of the Galleri multi-cancer early detection (MCED) test.
Learn more: grail.com/press-releas...
Learn more: grail.com/press-releas...
GRAIL is the 2025 Best Overall MedTech Company! We are so proud of this recognition from the 9th annual MedTech Breakthrough Awards program, which is designed to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories.
May 9, 2025 at 4:22 PM
GRAIL is the 2025 Best Overall MedTech Company! We are so proud of this recognition from the 9th annual MedTech Breakthrough Awards program, which is designed to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories.